Clinical trials: Glomerular Disease
Chronic Renal Failure
the Effect of Calcium Dobesilate on Non Dialysis Patients With CKD
To investigate the feasibility of calcium dobesilate in the treatment of microvascular injury provides new ideas and theoretical basis for the prevention and treatment of chronic renal failure.
- Trial name
- NCT03427944
- Testing
- Calcium Dobesilate group, Conventional Treatment group
- Where
- China
- Volunteers
- 100 people
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
Polycystic Ovary Syndrome, Urine Albumin \(UAlb\)
Urine Albumin/Creatinine Ratio and Renal Function Differences in Phenotypes of Polycystic Ovary Syndrome.
Since there are different metabolic effects in different phenotypes of polycystic ovary syndrome (PCOS); in this study; the investigators aimed to investigate whether there is a difference between glomerular filtration rate…
- Conditions
- Polycystic Ovary Syndrome, Urine Albumin \(UAlb\), Urine Creatinine \(UCr\), Glomerular Filtration Rate
- Trial name
- NCT07441811
- Where
- Turkey (Türkiye)
- Volunteers
- 300 people
- Sponsor
- Uşak University
Lupus Nephritis, Immunoglobulin A Nephropathy
An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases
The goal of this clinical study is to evaluate multiple dose levels of povetacicept in adults with immunoglobulin A (IgA) nephropathy (IgAN), primary membranous nephropathy (pMN), lupus-related kidney disease (lupus nephritis …
- Conditions
- Lupus Nephritis, Immunoglobulin A Nephropathy, Membranous Nephropathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Trial name
- RUBY-3 (NCT05732402)
- Testing
- Povetacicept
- Where
- 30 sites in United States, Australia and 2 more
- Volunteers
- 72 people
- Sponsor
- Alpine Immune Sciences, Inc.
Chronic Kidney Diseases
ProtocoL for GFR Measurement Using Iohexol (SCOPE-PLUS) - A Substudy of the SCOPE Study
SCOPE-PLUS is an optional substudy of the observational SCOPE Study (Screening for Chronic Kidney Disease among Older People across Europe, NCT02691546).
- Trial name
- SCOPE-PLUS (NCT04449172)
- Where
- 5 sites in Austria, Italy and 2 more
- Volunteers
- 100 people
- Sponsor
- Istituto Nazionale di Ricovero e Cura per Anziani
Chronic Kidney Disease
Study of Atorvastatin Dose Dependent Reduction of Proteinuria
Randomized controlled double blind study of parallel groups to evaluate the comparative effects of low-dose of atorvastatin on proteinuria in patients with stage 3 or 4 chronic kidney disease.
- Trial name
- SARP (NCT00768638)
- Testing
- Atorvastatin
- Where
- Canada
- Volunteers
- 23 people
- Sponsor
- Laval University
Chronic Kidney Disease
Impact of Increased Water Intake in Chronic Kidney Disease
The investigators have designed a randomized controlled trial to test whether increased water intake slows renal decline in patients with Stage-III Chronic Kidney Disease.
- Trial name
- WIT (NCT01766687)
- Testing
- Hydration
- Where
- Canada
- Volunteers
- 822 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Chronic Kidney Disease, Type 2 Diabetes
A Pharmacodynamic Study of Measured Glomerular Filtration Rate in Patients With Chronic Kidney Disease and Type 2 Diabetes
This is a 24-week multi-center, double-blind, randomized, exploratory study of bardoxolone methyl treatment in 18 patients with Stage 3 CKD (eGFR greater than or equal to 30.0 to less than 60.0 ml/min/1.73m2) and diabetes to…
- Trial name
- NCT01500798
- Testing
- 20 mg bardoxolone methyl
- Volunteers
- 18 people
- Sponsor
- Biogen
Renal Function Disorder
Development and Validation of Creatinine-Based Estimates of the Glomerular Filtration Rate Equation
This study aim to recruit all Electronic Medical Record of patients who underwent for 51chromium ethylenediamine tetra acetic acid (51Cr-EDTA) imaging at the Nuclear Medicine Centre, University Malaya Medical Centre from…
- Trial name
- NCT05112393
- Testing
- Development of new estimating Glomerular Filtration Rate (eGFR) equation, Validation of new estimating Glomerular Filtration Rate (eGFR) equation
- Where
- Malaysia
- Volunteers
- 200 people
- Sponsor
- University of Malaya
Autoimmune Diseases
Complement C5 mAb in the Treatment of Anti-GBM Disease
Anti-GBM disease is the most severe form of glomerulonephritis. Despite of the standard treatment including plasmapheresis and immunosuppressant, 70% of the patients still go into end-stage kidney disease.
- Trial name
- NCT06513338
- Testing
- Eculizumab
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Peking University First Hospital
Kidney Disease
A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases
Three kidney diseases that affect both children and adults are minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS) and membranous nephropathy (MN).
- Trial name
- NCT02639260
- Testing
- N-acetyl D-mannosamine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Kidney Transplantation
Chronic Transplant Glomerulopathy and Regulation of Expression of Ephrin B1
The principal purpose is the study of the regulation of the expression of ephrin-B1 by immunofluorescence in kidney biopsies of patients with Chronic transplant glomerulopathy (CTG) compared to biopsies prior to the CTG, in same…
- Trial name
- GARRE (NCT02147210)
- Testing
- biological analysis
- Where
- France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Toulouse
Cannabis, Chronic Kidney Diseases
The Pharmacokinetics of Single Dose Oral Tetrahydrocannabinol and Cannabidiol
POT-GFR-PK is a single dose pharmacokinetic study oral tetrahydrocannabinol (THC) and cannabidiol (CBD) in healthy adult controls and individuals with chronic kidney disease including those treated with in-center hemodialysis.
- Conditions
- Cannabis, Chronic Kidney Diseases, Dialysis
- Trial name
- POT-GFR-PK (NCT05742724)
- Testing
- Tetrahydrocannabinol-Cannabidiol Combination
- Where
- Canada
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- McMaster University
Obesity
Effect of VI-0521 (Qsymia®) on Glomerular Filtration Rate (GFR) in Overweight or Obese Healthy Subjects
The main purpose of this study is measure the effect of VI-0521 on kidney function. Specifically, glomerular filtration rate (GFR) will be measured at baseline, after 4 weeks of study treatment, and after an additional 4 weeks of…
- Trial name
- NCT02229214
- Testing
- Qsymia
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- VIVUS LLC
Renal Impairment
A Pharmacokinetic Study of YM178 in Normal Subjects and Those With Mild, Moderate, and Severe Renal Impairment
The objective of this study is to assess and compare the pharmacokinetic properties of YM178 in normal subjects and those with mild, moderate and severe renal impairment.
- Trial name
- NCT00750620
- Testing
- YM178
- Where
- 2 sites in United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc
Glomerular Filtration Rate, Acute Kidney Injury
Pharmacokinetics of MP-3180 and Use of Noninvasive Fluorescence Detection Device in Healthy Volunteers
The purpose of this early feasibility study was to investigate the pharmacokinetics of MP-3180 administered in rising doses and to evaluate the use of the Optical Renal Function Monitor (ORFM), an investigational noninvasive…
- Trial name
- ORFM-1B (NCT02098187)
- Testing
- Below target dose MP-3180, At target dose MP-3180, 2 times above target dose MP-3180
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- MediBeacon
Hypertension
Autoregulation of Glomerular Filtration Rate in Patients With Type 1 Diabetes During Spironolactone Therapy
To evaluate the impact of spironolactone treatment on renal autoregulation in hypertensive type 1 diabetic patients.
- Trial name
- NCT00335413
- Testing
- Spironolactone
- Volunteers
- 17 people
- Sponsor
- Steno Diabetes Center Copenhagen
Kidney Disease, Albuminuria
Tetrahydrobiopterin in Patients With Chronic Kidney Disease (CKD) and Albuminuria
Patients with chronic kidney disease (CKD) and albuminuria are at increased risk of developing cardiovascular disease (CVD) which is often associated with hypertension, left ventricular hypertrophy, endothelial dysfunction and…
- Trial name
- NCT00625820
- Testing
- 6R BH4, Vitamin C
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Michigan
Obesity, Bariatric Surgery
Impact of Weight Loss After a Bypass Surgery on Renal Hemodynamic Under Stress Conditions
The sympathetic nervous (SNS) and the renin angiotensin aldosterone system (RAS) have a direct impact on renal hemodynamic, hormonal secretion and vasoactive peptide.
- Conditions
- Obesity, Bariatric Surgery, Blood Pressure
- Trial name
- OBBYSS (NCT02218112)
- Testing
- bariatric surgery (gastric bypass)
- Where
- Switzerland
- Volunteers
- 36 people
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Transplant Recipient (Kidney), Primary Kidney Transplantation
Posttranslationally Modified Fetuin-A in Urine as a Marker for Renal Dysfunction (Patients With Chronic Kidney Disease - With or Without Kidney Transplantation).
Kidney transplantation is the preferred treatment method for patients with chronic kidney disease. Standard parameters (estimated glomerular filtration, albuminuria) of renal function detection are limited by many factors…
- Trial name
- (uPTM-FetA) (NCT06950931)
- Testing
- uPTM-FeA
- Where
- Slovakia
- Volunteers
- 86 people
- Sponsor
- University Hospital, Martin
IgAN, Immunoglobulin A Nephropathy (IgAN)
Efficacy and Safety Study of HS-10542 for IgA Nephropathy
This is a multicenter, randomized, double-blind, parallel, placebo-controlled study and is being conducted to evaluate the efficacy and safety of HS-10542 capsules for primary IgA nephropathy.
- Conditions
- IgAN, Immunoglobulin A Nephropathy (IgAN), Glomerular Disease
- Trial name
- HS-10542 (NCT07474636)
- Testing
- HS-10542 High Dose, HS-10542 Low Dose
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.